TCGA-AN-A0FN-01A-11R-A034-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 7
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.680
- ANGIOGENESIS+0.610
- ALLOGRAFT_REJECTION+0.580
- TNFA_SIGNALING_VIA_NFKB+0.550
- INFLAMMATORY_RESPONSE+0.520
- KRAS_SIGNALING_UP+0.520
- IL6_JAK_STAT3_SIGNALING+0.510
- TGF_BETA_SIGNALING+0.500
- COAGULATION+0.480
- COMPLEMENT+0.480
Top 10 suppressed
- MYC_TARGETS_V2-0.680
- E2F_TARGETS-0.590
- MYC_TARGETS_V1-0.570
- G2M_CHECKPOINT-0.540
- OXIDATIVE_PHOSPHORYLATION-0.430
- DNA_REPAIR-0.420
- MTORC1_SIGNALING-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.330
- GLYCOLYSIS-0.320
- PEROXISOME-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.960 |
| 2 | SRR8518425 | — | A | 0.953 |
| 3 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.951 |
| 4 | C3N-02923 | — | cohortMD2 | 0.943 |
| 5 | TCGA-D8-A141-01A-11R-A115-07 | — | A | 0.943 |
| 6 | TCGA-AC-A3HN-01A-11R-A213-07 | — | A | 0.943 |
| 7 | GSM6454738 | — | A | 0.942 |
| 8 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.941 |
| 9 | TCGA-BH-A6R9-01A-21R-A32P-07 | — | A | 0.938 |
| 10 | TCGA-BH-A0DI-01A-21R-A12P-07 | — | A | 0.938 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.680 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.610 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.550 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.520 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.520 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.510 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| COAGULATION | 0.480 | Binimetinib | — uncovered |
| COMPLEMENT | 0.480 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.470 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.450 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.400 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| APOPTOSIS | 0.350 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |